KYBELLA™

What is KYBELLA™?

KYBELLA™ is the first and only FDA approved injectable drug that contours and improves the appearance of submental fullness.

What is submental fullness?
Patients asking about their submental fullness may, at times, refer to it as their “double chin.”
It is a common, yet undertreated facial aesthetic condition that can:
> Detract from an otherwise balanced and harmonious facial appearance
> Lead to an older and heavier look
> Impact a broad range of adults, including both women and men
> Be caused by aging, genetics and/or weight gain

How does KYBELLA™ work?

KYBELLA™ is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, KYBELLA™ causes lysis of adipocytes, the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.

What should I expect after the treatment?

For most patients, downtime with KYBELLA™ was minimal and occurred most commonly after the first treatment session. The most common side effects are swelling, bruising, pain, numbness, redness, and areas of hardness in the treatment area.

GALLERY


KybellaFront KybellaFront1 KybellaSide KybellaSide1

KYBELLA™ Important Safety Information

IMPORTANT SAFETY INFORMATION

KYBELLA™ should only be administered by a trained healthcare professional.
KYBELLA™ is contraindicated in the presence of infection at the injection sites.
Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage.
Causes of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA™ should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported form the trials resolved spontaneously (range 1-298 days, median 44 days).
Difficulty swallowing (dysphagia) occured in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Causes of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA™ in these patients as current or prior history of dysphagia may exacerbate the condition.

Hours of Operation

Monday: 9 AM - 6 PM
Tuesday: 9 AM - 7 PM
Wednesday: 9 AM - 6 PM
Thursday: 9 AM - 7 PM
Friday: 9 AM - 6 PM
Saturday: By Appointment Only
Sunday: Closed

LATEST NEWS

Ask Us!

Name & Tel. No.

Email

Message

captcha

BLAKE BESSAN DESIGNS